tbuckley/cabot-search huggingface dataset:
Predictive factors of failure of conservative management in patients with emphysemtous pyelonephritis
Authors: M.H. Saadi, A. Saadi, M. Chakroun, B. Saidani, M. Jrad, A. Bouzouita, A. Derouiche, R. Ben Slama, H. Ayed, M. Chebil
Journal: European Urology (2021)
Targeting Residual Chemotherapy-Resistant Acute Myeloid Leukemia Cells By a Novel Oxphos Inhibitor IACS010759
Authors: Lina Han, Antonio Cavazos, Natalia Baran, Qi Zhang, Vinitha Mary Kuruvilla, Ningping Feng, Venkata Lokesh Battula, Michael Andreeff, Hagop M. Kantarjian, Naval Daver, Joseph R Marszalek, Marina Konopleva
Journal: Blood (2017)
Abstract 711: Repurposing 2nd generation androgen receptor antagonist Proxalutamide to treat COVID-19
Authors: Liandong Ma, Youzhi Tong, Qiang Guo, Yifeng Zhou, Qianxiang Zhou, Honghua Yan
Journal: Cancer Research (2021)

Abstract To date, as of 17 November 2020, there have been 55 million confirmed cases of COVID-19, including 1,4 million deaths globally, as reported to WHO. It is, therefore, very critical to discovery and development of the available treatment options for COVID-19. We here discuss the repurposing 2nd generation androgen receptor antagonist Proxalutaminde to treat COVID19. We analyzed the gender disparity of disease severity and progression in 1339 patients with COVID-19 and investigated the mechanism of gender disparity in male vs female patients with COVID 19. As androgen-androgen receptor pathway may contribute to the difference in severity and disease progression in male and female patients with COVID-19, we used cell lines derived from lung, prostate cancer and normal lung epithelial cells to determine the effect of androgen and androgen receptor antagonist Proxalutamide on the expression of two key proteins for SARS-CoV-2 to infect and enter the host cells. Angiotensin converting enzyme 2 (ACE2), a host transmembrane protein provides the binding sites for SARS-CoV-2 on the host cell surface, transmembrane protease serine 2 (TMPRSS2), a cellular serine protease, prims the S protein of SARS-Cov-2 to facilitate the viral entry into the host cells. As cytokine store plays a major role in the disease progression of COVID-19, we examined the effect of GT0918 on inducible nitric oxide synthase (iNOS) and Tumor necrosis factor-alpha (TNF-α), the macrophage polarization/activation markers, in mouse macrophage cells. In this study, we demonstrated higher rates of disease progression and mortality of male COVID-19 patients than female patients. Furthermore, we revealed that androgen-AR activation induced the expression of ACE2 and TMPRSS2 under the androgen-dependent condition in cells derived from prostate and lung cancer, which was inhibited by the blockage of AR signaling with Proxalutamide. Importantly, Proxalutamide also inhibited the expression of iNOS and TNF-α, the biomarkers for macrophage polarization/activation. These results support the role of androgen-AR signaling in the disease progression and mortality in male patients with COVID-19. We are currently conducting clinical study in COVID-19 patients with Proxalutamide in Brazil (NCT04446429). Citation Format: Liandong Ma, Youzhi Tong, Qiang Guo, Yifeng Zhou, Qianxiang Zhou, Honghua Yan. Repurposing 2nd generation androgen receptor antagonist Proxalutamide to treat COVID-19 [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 711.
Potential role of a clinical, taxonomical classification and RNA expression integrated signature to predict response to neoadjuvant platinum-based chemotherapy in Muscle-Invasive Bladder Cancer (MIBC) patients
Authors: J.L. Gago Ramos, A. Font, M. Domenech, C. Carrato, J.L. Ramírez, B. Cadenas, M. Calle, N. Malats, F.X. Real
Journal: European Urology (2021)
Transforming growth factor-β-regulated mTOR activity preserves cellular metabolism to maintain long-term T cell responses in chronic infection
Authors: Sarah S. Gabriel, Carlson Tsui, David Chisanga, Flora Weber, Manuela Llano-León, Patrick M. Gubser, Laurent Bartholin, Fernando Souza-Fonseca-Guimaraes, Nicholas D. Huntington, Wei Shi, Daniel T. Utzschneider, Axel Kallies
Journal: Immunity (2021)
Immune Checkpoint Inhibitor Therapy Toxicities—Reply
Authors: Adam S. Cifu, Anne R. Bass, Pankti D. Reid
Journal: JAMA (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
ヒト免疫不全ウイルス患者における新しいC型肝炎ウイルス感染の肝硬変への発生率と進行【Powered by NICT】
Authors: M Puoti, P Lorenzini, A Cozzi-Lepri, A Gori, C Mastroianni, G Rizzardini, G Mazzarello, A Antinori, A d’Arminio Monforte, E Girardi
Journal: Clinical Microbiology and Infection (2017)
インターロイキン17Aは病原性T細胞を促進するIL-1β産生骨髄細胞を動員することにより自己免疫におけるプライミングの役割を果たす【JST・京大機械翻訳】
Authors: M McGinley Aoife, E Sutton Caroline, C Edwards Sarah, M Leane Charlotte, DeCourcey Joseph, Teijeiro Ana, A Hamilton John, Boon Louis, Djouder Nabil, H G Mills Kingston
Journal: Immunity (2020)
만성 B형 간염에서 라미부딘의 치료반응 예측 인자로서 치료 전 ALT치와 조직학적 간염 활성도
Authors: 권영오, Kyunghee Kang
Journal: Clinical and Molecular Hepatology (2004)

목적: 현재 만성 B형 간염의 치료에 최근에 널리 사용되고 있는 라미부딘의 경우 바이러스 증식을 억제하는 효과는 뛰어나나 1년 치료시 약 15- 30%, 3년 후에는 50%까지의 내성 발현율을 보이고 있어 치료반응을 예측할 수 있는 인자를 통해 적절한 치료 대상자를 선택하는 것이 중요한 문제이다. 그러나 아직까지 그러한 예측 인자들에 대한 연구 결과들은 많지 않은 실정이다. 이에 저자들은 치료 전 조직학적 소견을 포함하여 어떤 인자들이 라미부딘 치료에
Co-delivery of novel bispecific and trispecific engagers by an amplicon vector augments the therapeutic effect of an HSV-based oncolytic virotherapy
Authors: Divya Ravirala, Brandon Mistretta, Preethi H Gunaratne, Guangsheng Pei, Zhongming Zhao, Xiaoliu Zhang
Journal: Journal for ImmunoTherapy of Cancer (2021)

Although oncolytic virotherapy has shown substantial promises as a new treatment modality for many malignancies, further improvement on its therapeutic efficacy will likely bring more clinical benefits. One plausible way of enhancing the therapeutic effect of virotherapy is to enable it with the ability to concurrently engage the infiltrating immune cells to provide additional antitumor mechanisms. Here, we report the construction and evaluation of two novel chimeric molecules (bispecific chimeric engager proteins, BiCEP and trispecific chimeric engager protein, TriCEP) that can engage both natural killer (NK) and T cells with tumor cells for enhanced antitumor activities. BiCEP was constructed by linking orthopoxvirus major histocompatibility complex class I-like protein, which can selectively bind to NKG2D with a high affinity to a mutant form of epidermal growth factor (EGF) that can strongly bind to EGF receptor. TriCEP is similarly constructed except that it also contains a modified form of interleukin-2 that can only function as a tethered form. As NKG2D is expressed on both NK and CD8+ T cells, both of which can thus be engaged by BiCEP and TriCEP. Both BiCEP and TriCEP showed the ability to engage NK and T cells to kill tumor cells in vitro. Coadministration of BiCEP and TriCEP with an oncolytic herpes simplex virus enhanced the overall antitumor effect. Furthermore, single-cell RNA sequencing analysis revealed that TriCEP not only engaged NK and T cells to kill tumor cells, it also promotes the infiltration and activation of these important immune cells. These novel chimeric molecules exploit the ability of the oncolytic virotherapy in altering the tumor microenvironment with increased infiltration of important immune cells such as NK and T cells for cancer immunotherapy. The ability of BiCEP and TriCEP to engage both NK and T cells makes them an ideal choice for arming an oncolytic virotherapy.
Breakthrough SARS-CoV-2 Infections in Prison after Vaccination
Authors: Lauren Brinkley-Rubinstein, Meghan Peterson, Rosemarie Martin, Philip Chan, Justin Berk
Journal: New England Journal of Medicine (2021)

SARS-CoV-2 Positivity after Vaccination in a Prison In this study involving 2380 vaccinated persons in a Rhode Island prison complex, there were 27 breakthrough cases of Covid-19, all of which were...
Management of women with overactive bladder syndrome: A systematic review with meta-analysis of benefits and potential harms of surgical and non-surgical treatment options by the EAU non-neurogenic female LUTS Guidelines panel
Authors: F. Farag, V.I. Sakalis, N. Sihra, M. Karavitakis, S. Monagas, C. Yuan, M. Manso, A. Nic An Riogh, E. O’Connor, L. Tzelves, K.H. Pang, R. Campi, S. Arlandis, K. Bo, E. Costantini, J. Groen, B. Peyronnet, V. Phé, C.H. Van Der Vaart, M.C. Lapitan, A. Nambiar, M.I. Omar, C.K. Harding
Journal: European Urology (2021)
Abstract 672: Prognostic significance of urokinase plasminogen activator system in a naturally occurring model of osteosarcoma
Authors: Arata Matsuyama, Anthony J. Mutsaers
Journal: Cancer Research (2021)

Abstract Introduction Human pediatric and canine osteosarcoma (OSA) are both highly metastatic primary bone cancers that share molecular and clinical similarities. Urokinase plasminogen activator (uPA) and its receptor uPAR promote invasion, metastasis and angiogenesis in multiple cancer types and have been shown to play critical roles in malignant characteristics of OSA in vitro, yet their clinical significance has not been investigated in OSA patients. Methods Serum samples of dogs with naturally-occurring appendicular OSA (n=26) and clinically healthy dogs (n=6) were analyzed using commercially available canine-specific ELISA and uPA activity kits. Dogs with OSA that presented without metastatic disease at diagnosis and received treatment with amputation plus adjuvant carboplatin chemotherapy were included. Survival data and patient characteristics were obtained from medical records. Differences in serum uPA/uPAR results between the groups was tested by t test or Wilcoxan rank sum test. Kaplan Meier survival curve and log rank test were used for survival analysis in the OSA cohort after subgrouping by X-Tyle software. Well-established prognostic factors and serum uPA/uPAR results were tested for prognostic significance by cox regression analysis in both univariate and multivariate analyses. Results Dogs with OSA had significantly higher serum uPA (p=0.008; 1905.4 vs 1439.5 pg/mL) but not uPAR (p=0.866) levels compared to healthy dogs. OSA-bearing dogs with high serum uPA had significantly shorter progression-free (p=0.003; 94 vs 266 days) and overall survival (p=0.01; 123 vs 338 days) than dogs with low uPA level. Similarly, dogs with high serum uPA activity had significantly shorter progression-free survival (p=0.043; 227 vs 266 days). Serum uPAR was not prognostic in this cohort. Multivariate analysis revealed increased serum uPA level (p=0.024) as a poor prognostic indicator in addition to other established prognostic factors in dogs such as humeral location (p=0.022) and increased monocyte count (p=0.015). Conclusions Circulating uPA quantity and activity are increased in canine OSA patients with more aggressive disease, indicating importance of the uPA system in OSA disease progression. While an OSA-associated increase in circulating uPAR was not evident, this receptor likely contributes to OSA malignancy subsequent to the increased uPA ligand production. Serum uPA may be an attractive prognostic biomarker in OSA and the up-regulated uPA/uPAR axis should be further investigated as a potential therapeutic target for this disease. Citation Format: Arata Matsuyama, Anthony J. Mutsaers. Prognostic significance of urokinase plasminogen activator system in a naturally occurring model of osteosarcoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 672.
ROX monitoring in critical COVID-19 patients treated with high flow oxygen: A real added value compared to the respiratory rate?
Authors: M. Garnier, D. Blez
Journal: Pulmonology (2021)

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not.The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.L'archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés. ROX monitoring in critical COVID-19 patients treated with high flow oxygen: A real added value compared tothe respiratory rate?M. Garnier, D. Blez
Administration of Supplemental Oxygen
Authors: Sundara Rengasamy, Bishoi Nassef, Federico Bilotta, Francesco Pugliese, Ala Nozari, Rafael Ortega
Journal: New England Journal of Medicine (2021)

Supplemental oxygen is commonly used and is fundamental to the treatment of hypoxemia. This video focuses on the administration of supplemental oxygen in adult patients in an acute care setting through a nasal cannula, simple face mask, face tent, Venturi mask, nonrebreather face mask, and high-flow nasal cannula.
Abstract 1102: Integrated approach towards defining mechanism based combinations to guide clinical development of glutaminase inhibitors
Authors: Jeffrey J. Kovacs, Nakia D. Spencer, Christopher A. Bristow, Alessandro Carugo, Virginia Giluiani, Meredith A. Miller, Angela Harris, Ningping Feng, Michael L. Soth, Kang Le, Elisa de Stanchina, Charles M. Rudin, Giulio Draetta, Timothy A. Yap, Philip Jones, Timothy Heffernan
Journal: Cancer Research (2021)

Abstract Metabolic dysregulation is a hallmark of cancer, and recently, increasing evidence has shown a critical role for glutamine metabolism to support the bioenergetics and biosysnthetic needs of tumor and immune cells. We have previously disclosed the development of the GLS1 inhibitor, IPN60090, which is currently advancing through Phase 1 clinical studies (NCT03894540). Metabolic plasticity has been suggested to confer adaptive resistance to metabolic inhibitors and defines mechanisms that could be exploited to enhance therapeutic benefit. To address the clinical problems of innate drug resistance and adaptation, we interrogated metabolic and adaptive responses to IPN60090 in vitro and in vivo. We and others have previously identified KEAP1/NFE2L2 mutant non-small cell lung cancer models as sensitive to GLS1 inhibition. Through an integrated approach, including metabolic, transcriptomic, and proteomic analysis, we have identified molecular pathways that confer resistance to GLS1 inhibition. Nodes in these pathways that drive aquired resistance, may serve as additional patient stratification biomarkers in subsets on NSCLC or provide opportunites for further drug development. Additionally, unbiased in vivo functional genomics screening identified mulitple signaling pathways that act as critical nodes governing resistance to GLS1 inhibition. Drug combinations were tested in vitro and in vivo to identify those that are most synergistic with IPN60090. We found that PI3K/AKT/mTOR signaling is a major contributor to IPN60090 resistance, and we demonstrate that dual targeting of GLS1 and PI3K/AKT/mTOR signaling in tumors with KEAP1/NFE2L2 mutations results in synergistic anti-tumor efficacy. IPN60090, dosed in combination with inhibitors of these pathways yields regressions and off-treatment, durable responses in preclinical models of KEAP1-mutant NSCLC. Based on these data, combination strategies are being developed for Phase 1b expansion cohorts. Citation Format: Jeffrey J. Kovacs, Nakia D. Spencer, Christopher A. Bristow, Alessandro Carugo, Virginia Giluiani, Meredith A. Miller, Angela Harris, Ningping Feng, Michael L. Soth, Kang Le, Elisa de Stanchina, Charles M. Rudin, Giulio Draetta, Timothy A. Yap, Philip Jones, Timothy Heffernan. Integrated approach towards defining mechanism based combinations to guide clinical development of glutaminase inhibitors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 1102.
Abstract 1043: Enhancing cytotoxic chemotherapy effects by nintedanib in gastric cancer preclinical models
Authors: Niranjan Awasthi, Margaret A. Schwarz, Frank Hilberg, Roderich E. Schwarz
Journal: Cancer Research (2021)

Abstract Background: Gastric adenocarcinoma (GAC) remains the 3rd most common cause of cancer mortality in the world. Systemic chemotherapy is a preferred treatment option for advanced and recurrent GAC, but response rates and survival extension remain limited. Tumor angiogenesis plays a critical role in GAC growth, invasion and metastasis. In this study, we determined the antitumor efficacy of nintedanib, a potent triple angiokinase inhibitor for VEGFR-1/2/3, PDGFR-α/β and FGFR-1/2/3, alone or in combination with chemotherapy, in preclinical models of GAC. Methods: Animal survival and tumor growth studies were performed in 4-6 week-old female NOD/SCID mice with human GAC cell xenografts (MKN-45, KATO-III, SNU-5). The mechanistic evaluation involved Immunohistochemistry and Immunoblot analyses of subcutaneous tumors. In vitro cell viability assays were performed using colorimetric WST-1 reagent. Results: In MKN-45 cell-derived peritoneal dissemination xenografts, animal survival was improved by nintedanib (33%), docetaxel (100%) or irinotecan (181%), while oxaliplatin, 5-FU and epirubicin had no effect. The addition of nintedanib to docetaxel (157%) or irinotecan (214%) led to a further extension in animal survival. In KATO-III cell-derived xenografts carrying FGFR2 gene amplification, nintedanib monotherapy extended survival much more (209%). Docetaxel and irinotecan effects were again further enhanced by nintedanib. In MKN-45 subcutaneous xenografts, nintedanib, epirubicin, docetaxel or irinotecan reduced tumor growth (range: 68-87%), while 5-FU and oxaliplatin had a smaller effect (40%). The addition of nintedanib to all chemotherapy groups demonstrated a further reduction in tumor growth. Subcutaneous tumor analysis revealed that nintedanib attenuated tumor cell proliferation, reduced tumor vasculature and increased tumor cell death. Nintedanib (10 μM) inhibited in vitro cell proliferation of mutationally different GAC cells by 25% (MKN-45), 75% (KATO-III) or 82% (SNU-5), and confirmed additive inhibitory effects in combinations with chemotherapy agents. Conclusion: Nintedanib showed notable antitumor efficacy and significantly improved taxane or irinotecan chemotherapy responses. Combination regimens with nintedanib have the potential for improving clinical GAC therapy. Citation Format: Niranjan Awasthi, Margaret A. Schwarz, Frank Hilberg, Roderich E. Schwarz. Enhancing cytotoxic chemotherapy effects by nintedanib in gastric cancer preclinical models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 1043.
Peripheral blood leucocyte telomere length is associated with progression of interstitial lung disease in systemic sclerosis
Authors: Shuo Liu, Melody P Chung, Brett Ley, Sarah French, Brett M Elicker, David F Fiorentino, Lorinda S Chung, Francesco Boin, Paul J Wolters
Journal: Thorax (2021)

Background Peripheral blood leucocyte telomere length (PBL-TL) is associated with outcomes in patients with idiopathic pulmonary fibrosis. Whether PBL-TL is associated with progression of systemic sclerosis-associated interstitial lung disease (SSc-ILD) is unknown. Methods A retrospective observational cohort study was performed using prospectively collected data from 213 patients with SSc followed at the University of California San Francisco (UCSF) Scleroderma Center. PBL-TL was measured by quantitative PCR of DNA isolated from peripheral blood. Associations between PBL-TL and pulmonary function test trends in patients with SSc-ILD were assessed by longitudinal analysis using Generalised Linear Mixed Models. Findings were validated in a cohort of 61 patients with SSc-ILD enrolled in the Stanford University Scleroderma Center database. Results Patients with UCSF SSc with ILD were found to have shorter PBL-TL compared with those without ILD (6554±671 base pairs (bp) vs 6782±698 bp, p=0.01). Shorter PBL-TL was associated with the presence of ILD (adjusted OR 2.1 per 1000 bp TL decrease, 95% CI [1.25 to 3.70], p=0.006). PBL-TL was shorter in patients with SSc-ILD lacking SSc-specific autoantibodies compared with seropositive subjects (6237±647 bp vs 6651±653 bp, p=0.004). Shorter PBL-TL was associated with increased risk for lung function deterioration with an average of 67 mL greater loss in per year for every 1000 bp decrease in PBL-TL in the combined SSc-ILD cohorts (longitudinal analysis, adjusted model: 95% CI −104 mL to −33 mL, p&lt;0.001). Conclusions These findings suggest that telomere dysfunction may be associated with SSc-ILD progression and that PBL-TL measurement may be useful for stratifying risk for SSc-ILD progression.
MRI and targeted biopsies compared to transperineal mapping biopsies for targeted ablation in recurrent prostate cancer after radiotherapy: Primary outcomes of the FORECAST trial
Authors: T.T. Shah, A. Kanthabalan, M. Pavlou, S. Adeleke, F. Giganti, C. Brew-Graves, N.R Williams, A. Haroon, H. Sidhu, A. Freeman, C. Orczyk, A. Nikapota, T. Dudderidge, R. Hindley, J. Virdi, M. Arya, A. Mitra, H. Payne, J. Bomanji, M. Winkler, G. Horan, C. Moore, M. Emberton, S. Punwani, H.U Ahmed
Journal: European Urology (2021)
A multicenter, propensity score-matched retrospective study of preventing postoperative infection in robotic and laparoscopic minimally invasive surgeries; double-versus single-gloving
Authors: T. Nagai, K. Taguchi, T. Isobe, N. Matsuyama, T. Hattori, R. Unno, T. Kato, T. Etani, T. Hamakawa, Y. Fujii, Y. Ikegami, H. Kamiya, S. Hamamoto, A. Nakane, R. Ando, T. Maruyama, A. Okada, N. Kawai, T. Yasui
Journal: European Urology (2021)
肥大型心筋症患者における心筋線維症の神経ホルモン決定因子:Gd-DTPA造影MRIによる評価
Authors: Tsuyoshi M, Hamada M, Kurata A, Morioka K, Ohshima K, Inoue K, Ogimoto A, Ohtsuka T, Hara Y, Shigematsu Y, Matsumoto Y
Journal: Circulation (2003)